To compare the efficacy and safety of antithrombotic prophylaxis given for 1 week or 4 weeks in patients undergoing laparoscopic surgery for colorectal cancer.
Extending antithrombotic prophylaxis beyond 1 week reduces the incidence of venous thromboembolism (VTE) after open abdominal surgery for cancer.
In consecutive patients who underwent laparoscopic surgery for colorectal cancer, complete compression ultrasonography of the lower limbs was performed after 8 ± 2 days of antithrombotic prophylaxis. Patients with no evidence of VTE were randomized to short (heparin withdrawal) or to extended (heparin continued for 3 additional weeks) prophylaxis. Complete compression ultrasonography was repeated at day 28 ± 2 after surgery by investigators blinded to treatment allocation. The primary outcome of the study was the composite of symptomatic and ultrasonography-detected VTE at day 28 ± 2 after surgery.
Overall, 301 patients were evaluated for inclusion in the study and 225 were randomized. VTE occurred in 11 of 113 patients randomized to short (9.7%) and in none of the 112 patients randomized to extended heparin prophylaxis (P = 0.001). The incidence of VTE at 3 months was 9.7% and 0.9% in patients randomized to short or to extended heparin prophylaxis, respectively (relative risk reduction: 91%, 95% confidence interval: 30%–99%; P = 0.005). The rate of bleeding was similar in the 2 treatment groups. Two patients died during the study period, 1 in each treatment group.
After laparoscopic surgery for colorectal cancer, extended antithrombotic prophylaxis is safe and reduces the risk for VTE as compared with 1-week prophylaxis (NCT01589146).
One-week after a laparoscopic intervention for colorectal cancer, 225 patients were randomized to withdraw or to continue heparin prophylaxis for 3 additional weeks. Extended antithrombotic prophylaxis reduced the risk for venous thromboembolism as compared with 1-week prophylaxis without safety concerns.
*Internal and Cardiovascular Medicine-Stroke Unit, University of Perugia, Perugia, Italy
†Oncology Surgery, University of Perugia, Perugia, Italy
‡General Surgery, S. Maria della Misericordia Hospital, Perugia, Italy
§Unit of Angiology, University Hospital of Padua, Padua, Italy
¶General Surgery, Niguarda Hospital, Milan, Italy
‖General Surgery, S. Giovanni Battista Hospital, Foligno, Italy
**Unit of Angiology, S. Giovanni Battista Hospital, Foligno, Italy
††Department of Surgical, Oncological and Gastroenterological Sciences, Section of Surgical Clinic I, University Hospital of Padua, Padua, Italy
‡‡General and Emergency Surgery, University of Perugia, Perugia, Italy.
Reprints: Maria Cristina Vedovati, MD, Internal and Cardiovascular Medicine-Stroke Unit, University of Perugia, via G. Dottori 06123 Perugia. E-mail: email@example.com.
Disclosure: The authors declare no conflicts of interest regarding this paper.